<DOC>
	<DOCNO>NCT02261519</DOCNO>
	<brief_summary>The propose Phase IIb/III study design evaluate safety efficacy NaBen® improving symptom schizophrenia adult . NaBen® grant Breakthrough Therapy Designation US FDA add-on treatment schizophrenia . The trial design multi-center , prospective , randomize , placebo-controlled , adult subject schizophrenia enrol . The study include four part : 2 week Screening part , 4 week run-in part , 8 week double-blind treatment part , 52 week Open-Label Extension part .</brief_summary>
	<brief_title>Study Evaluate Safety &amp; Efficacy NaBen® Add-on Treatment Schizophrenia Adults</brief_title>
	<detailed_description>This adaptive , phase IIb/III , multi-center , prospective , randomize , placebo-controlled study , adult subject schizophrenia enrol . The study include four part : 2 week Screening part , 4 week run-in part , 8 week double-blind treatment part , 52 week Open-Label Extension part . Screening part study : The subject evaluate eligibility Screening part study . Enrichment run-in part study : Subjects determine eligible enter Run-in part study . A total 348 Subjects randomize . The randomized subject receive 4 week NaBen® Placebo accordingly . The subject complete 4 week randomize treatment group ( NaBen® Placebo ) assess categorized intoresponders non-responders , base 20 % reduction baseline PANSS total score per evaluation Visit 2 Visit 4 . Double-Blind treatment part study : - Subjects successfully complete Enrichment Run-in part enter Double- Blind treatment part study per : NaBen® treat subject : Subjects continue receive NaBen® another 8 week . - Placebo treated subject : - Placebo Responders : Subjects continue receive Placebo another 8 week . - Placebo Non-responders : Subjects re-randomized receive NaBen® Placebo 1:1 ratio another 8 week . Open-Label Extension part study : All subject complete Double-Blind part study continue Open-Label Extension part study receive NaBen® additional 52 week , plus 2 week follow-up .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Male/female subject 18 55 year age 2 . If female infertile ( define ) , subject must agree duration study use one follow form contraception 1 ) systemic hormonal treatment 2 ) Intrauterine device ( IUD ) implant least 2 month prior screen 3 ) `` doublebarrier '' contraception ( condom , diaphragm spermicide consider barrier ) . Females consider infertile either ) surgically sterile b ) spontaneous amenorrhea least last 2 year least 2 year onset amenorrhea receive hormone replacement therapy FollicleStimulating Hormone ( FSH ) level great 40 mIU/mL estradiol level le 30 pg/mL 3 . Subject capable providing informed consent willing sign ICF prior study Screening agree comply study protocol requirement 4 . Physician confirm DSMV diagnosis schizophrenia past 2 year base subject 's history confirm psychiatric evaluation MINI International Neuropsychiatric Interview For Schizophrenia Psychotic Disorders , version 7.0 ( MINI , Version 7.0 ) 5 . The subject outpatient hospitalization worsen schizophrenia within 3 month screening.If subject hospitalize study worsen schizophrenia symptom subject withdrawn study 6 . The subject 's schizophrenia condition clinically stable residual symptom . Residual symptom define total score ≤110 ≥ 60 PANSS per Visit 1 evaluation 7 . An unchanged antipsychotic medication regimen least eight ( 8 ) week prior screen study expect remain unchanged study ( longer depot longacting antipsychotic : ten ( 10 ) month Aripiprazole Paliperidone ; six ( 6 ) month Olanzapine pamoate monohydrate ; least 6 time duration report half life minimum four ( 4 ) month depot longacting antipsychotic ) 8 . In good general physical health without clinically significant abnormality physical exam , neurological exam laboratory assessment ( urine/blood routine , biochemical test ECG ) would exclude subject study opinion Investigator . For ALT AST , clinically significant define twice upper limit normal . 9 . BMI 17 35 inclusive 10 . Subject negative routine urine illicit drug screen test ( include heroin , amphetamine ( include MDMA/ecstasy ) , cocaine , cannabis PCP ) 11 . The subject caregiver identify responsible person ( e.g. , family member , social worker , caseworker nurse ) determine Investigator per local regulation . The identify caregiver consider reliable Investigator per local regulation provide support subject help ensure compliance study treatment , study visit protocol procedure preferably also able provide input helpful completing study rating scale 12 . The subject must danger self others per Investigator 's judgment 1 . Meets DSMIV V criterion screen intellectual disability , dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substanceinduced psychotic disorder , dementia , comorbid mental disorder opinion Investigator may interfere study conduct result interpretation 2 . Subjects whose illness resistant antipsychotic accord prior trial two different antipsychotic adequate dose 3 . Subjects previously treat receive clozapine 4 . Initiation dose change lithium , antidepressant mood stabilizer within 16 week prior screen 5 . Initiation dose change benzodiazepine sleep medication due worsen schizophrenia symptom medication side effect , psychotropic medication within 4 week prior screen 6 . The subject previously receive NaBen® 7 . History epilepsy , major head trauma , neurological illness Tourette 's syndrome might impair subject 's cognition psychiatric function per investigator 's judgment 8 . History allergic reaction sodium benzoate 9 . Serious medical illness endstage renal disease , liver failure heart failure , opinion Investigator , may interfere conduct study 10 . Any significant gastrointestinal disorder , opinion investigator , markedly alter absorption , metabolism elimination sodium benzoate 11 . Any movement disorder total score high 6 SAS scale , 2 item AIMS scale 12 . Current substance abuse , history meeting criterion moderate severe substance abuse ( include alcohol , exclude nicotine caffeine ) past six ( 6 ) month prior screen 13 . Female subject pregnant ( confirmed urine pregnancy test perform Screening Visit ) breast feed 14 . History cancer remission last 3 year except basal cell carcinoma squamous cell carcinoma 15 . Participation clinical trial within 3 month prior screen two clinical trial within 12 month 16 . Electroconvulsive Therapy within 6 month prior screen 17 . The subject start new nonmedication treatment schizophrenia psychiatric condition within last 3 month prior screen 18 . The subject 's antiEPS medication dose regimen change within 2 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>